NASDAQ:CAPR
Capricor Therapeutics Stock News
$5.24
-0.0900 (-1.69%)
At Close: May 02, 2024
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program
09:05pm, Thursday, 19'th Jan 2023 GlobeNewswire Inc.
-Company to present 18-month data results from ongoing HOPE-2 open label extension trial of CAP-1002 in patients with Duchenne muscular dystrophy-
Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform
02:26pm, Thursday, 12'th Jan 2023 GlobeNewswire Inc.
-StealthX™ Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins-
Capricor (CAPR) Upgraded to Buy: What Does It Mean for the Stock?
05:00pm, Wednesday, 11'th Jan 2023 Zacks Investment Research
Capricor (CAPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Capricor (CAPR) Upgraded to Buy: What Does It Mean for the Stock?
01:33pm, Wednesday, 11'th Jan 2023
Capricor (CAPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Capricor Therapeutics, Inc. (CAPR) Q3 2022 Earnings Call Transcript
10:21pm, Thursday, 10'th Nov 2022
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2022 Results Conference Call November 10, 2022 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - CEO Conference Call Participants Alan Leo
Capricor Therapeutics (CAPR) Reports Q3 Loss, Tops Revenue Estimates
10:15pm, Thursday, 10'th Nov 2022 Zacks Investment Research
Capricor (CAPR) delivered earnings and revenue surprises of 7.14% and 279.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Capricor Therapeutics (CAPR) Reports Q3 Loss, Tops Revenue Estimates
06:48pm, Thursday, 10'th Nov 2022
Capricor (CAPR) delivered earnings and revenue surprises of 7.14% and 279.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Capricor Therapeutics to Present Third Quarter 2022 Financial Results and Recent Corporate Update on November 10
04:01pm, Thursday, 03'rd Nov 2022
Company to Host Conference Call, November 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, November 10, 2022, at 4:30 p.m. ET
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022
02:07pm, Wednesday, 26'th Oct 2022 Benzinga
Upgrades
For Enterprise Financial Services Corp (NASDAQ:EFSC), DA Davidson upgraded the previous rating of Neutral to Buy. For the third quarter, Enterprise Finl Servs had an EPS of $1.32, compared to
Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022
01:00pm, Thursday, 06'th Oct 2022 GlobeNewswire Inc.
SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the tre
Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022
09:00am, Thursday, 06'th Oct 2022
SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treat
Capricor Therapeutics to Present at Upcoming Investor Conferences
12:00pm, Wednesday, 07'th Sep 2022 GlobeNewswire Inc.
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the tr
Capricor Therapeutics to Present at Upcoming Investor Conferences
08:00am, Wednesday, 07'th Sep 2022
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the trea
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2022 Results Earnings Call Transcript
08:21pm, Wednesday, 10'th Aug 2022
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Anthony Bergmann - CFO Linda Marbán - President and CEO Conference Call Par
Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
08:05pm, Wednesday, 10'th Aug 2022 GlobeNewswire Inc.
-First Patient Treated in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy-
